Effects of Individualized Training to Reduce Fatigue in Patients With Newly and Advanced Diagnosed Multiple Sclerosis
Condition(s) studied
Investigational drug(s) / intervention(s)
Traditional exercise: Patients will perform aerobic and resistance exercises that are consistent with the exercise guidelines for MS patients at home
Individualized exercise: Patients will performed a mobile-app guided program at home designed to address identified individual disabilities such as loss of muscle strength or cardiorespiratory deconditioning.
Study summary
Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system. It is characterized by complex and heterogeneous symptoms. Chronic fatigue is the most reported symptom in MS patients (80%). Current pharmacological treatments for MS patients reduce the number of relapses and their severity but do not improve symptoms such as fatigue. Physical activity is a therapy that helps reduce this fatigue, in addition to improving muscular and cardiorespiratory functions. However, the results are not optimal because MS patients remain less active than the general population. The improvement of the benefits of exercise therapy could therefore be based on three approaches: personalization of the training program, home practice and early initiation.
Eligibility
Primary outcome measure(s)
- Fatigue Severity Scale (FSS) — Week 15
Change in the chronic fatigue score assessed using the FSS questionnaire before and after the training programme. From 1 to 7. The higher the score, the greater the fatigue
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Chu de Saint-Etienne | Saint-Etienne | France | Recruiting |
More Centre Hospitalier Universitaire de Saint Etienne trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06201026 on ClinicalTrials.gov ↗ ← All trials in France